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Abstract
Thyroid hormone (TH) acts through specific receptors (TRs), which are conditional transcription
factors, to induce fibroblast growth factor 21 (FGF21), a peptide hormone that is usually
induced by fasting and that influences lipid and carbohydrate metabolism via local hepatic and
systemic endocrine effects. While TH and FGF21 display overlapping actions when administered,
including reductions in serum lipids, according to the current models these hormones act
independently in vivo. In this study, we examined mechanisms of regulation of FGF21 expression
by TH and tested the possibility that FGF21 is required for induction of hepatic TH-responsive
genes. We confirm that active TH (triiodothyronine (T3)) and the TRb-selective thyromimetic
GC1 increase FGF21 transcript and peptide levels in mouse liver and that this effect requires TRb.
T3 also induces FGF21 in cultured hepatocytes and this effect involves direct actions of TRb1,
which binds a TRE within intron 2 of FGF21. Gene expression profiles of WTand Fgf21-knockout
mice are very similar, indicating that FGF21 is dispensable for the majority of hepatic T3 gene
responses. A small subset of genes displays diminished T3 response in the absence of FGF21.
However, most of these are not obviously directly involved in T3-dependent hepatic metabolic
processes. Consistent with these results, T3-dependent effects on serum cholesterol are
maintained in the Fgf21K/K background and we observe no effect of the Fgf21-knockout
background on serum triglycerides and glucose. Our findings indicate that T3 regulates
the genes involved in classical hepatic metabolic responses independently of FGF21.
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Introduction
Fibroblast growth factor 21 (FGF21) is one of three
endocrine FGFs that influence metabolic responses via a
combination of local and systemic actions. FGF21 is
http://joe.endocrinology-journals.org
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expressed in the liver, pancreas, and white and brown
adipose tissue (Johnson et al. 2009, Fon Tacer et al. 2010,
Kliewer & Mangelsdorf 2010). Hepatic Fgf21 expression is
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induced by the nuclear hormone receptor peroxisome
proliferator-activated receptor a (PPARa) under fasting
conditions, and secreted FGF21 peptide exerts autocrine/
paracrine effects on liver, including regulation of genes
involved in lipogenesis, lipolysis, and fatty acid oxidation,
as well as additional endocrine effects on other tissues
(Badman et al. 2007). Administration of FGF21 to overweight and diabetic mice results in decreases in the levels of
plasma triglycerides and glucose, and increases in both
insulin sensitivity and thermogenesis associated with
decreased body weight (Coskun et al. 2008, Berglund et al.
2009, Xu et al. 2009). Conversely, mice that lack FGF21
exhibit late-onset obesity. Thus, there is intense interest in
FGF21 as a therapeutic for metabolic disorders, weight loss,
and diabetes. Potentially adverse effects of FGF21 have also
come to light. FGF21 is involved in integration of
metabolism and bone turnover, raising the possibility that
FGF21 could promote bone loss, and elevated FGF21 levels
are associated with abnormal lipid profiles in coronary heart
disease, raising concerns about cardiovascular events
(Iglesias et al. 2012, Wei et al. 2012). Moreover, FGF21 levels
become elevated in obesity and nonalcoholic fatty liver
disease, indicating that serum FGF21 levels do not always
correlate with an improved metabolic profile. Given these
concerns, it is important to understand how to manage
local production of FGF21 in desired target tissues and the
consequences of changes in FGF21 concentrations.
Thyroid hormones (THs) act as master regulators of
metabolism and there is evidence for interdependency of
TH and FGF21 signaling pathways. TH receptors (TRa and
TRb) are members of the nuclear hormone receptor family
that regulate target genes in response to the main active form
of TH, triiodothyronine (T3). TRs usually work by binding
DNA-response elements (TREs) in the proximal promoters of
target genes as heterodimers with retinoid X receptors (RXRs)
but can also regulate target genes via protein–protein
interactions with heterologous transcription factors (Baxter
& Webb 2009, Cheng et al. 2010, Lin et al. 2013). T3 induces
FGF21 in mouse liver and, in this study, TRb selectively
enhances FGF21 expression and promoter activity via
interactions with PPARa bound to PPARa-response elements,
but does not require PPARa to induce other T3-regulated
genes (Adams et al. 2010). In addition, FGF21 administration
to mice reduces serum levels of the parental form of TH,
thyroxine (T4), and T3, implying mutual regulatory dependency of these signaling systems (Domouzoglou et al. 2014).
In spite of these potential relationships, key actions of FGF21
and TH appear largely independent (Domouzoglou et al.
2014). Recent assessments of administration of TH to Fgf21knockout mice have revealed no differences in serum lipids,
http://joe.endocrinology-journals.org
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the expression of selected T3-regulated genes in liver and
brown adipose tissue, or overall energy expenditure.
Conversely, FGF21 elicited similar alterations in serum lipids
and gene expression in hypothyroid and euthyroid mice.
In this study, we set out to understand the mechanisms
and downstream effects of TH-dependent changes in hepatic
Fgf21 expression. We find that both T3 and the TRb-selective
thyromimetic GC1 act through TRb to directly induce
FGF21 expression and that the Fgf21 locus harbors a
functional TRE within intron 2. This finding added another
layer of complexity to previous studies of T3 regulation of
FGF21 expression, which indicated that TRb works primarily
through PPARa bound to the FGF21 promoter (Adams et al.
2010). While patterns of hepatic T3 responses are similar in
WT and Fgf21-knockout mice, similar to previous studies
of a subset of hepatic genes involved in lipid metabolism
(Domouzoglou & Maratos-Flier 2011, Domouzoglou et al.
2014), we also find that optimal response of a small subset
of hepatic TH-target genes requires Fgf21. These genes,
however, are not obviously related to metabolic regulation
and we find no changes in serum metabolic parameters
in Fgf21-knockout mice. Thus, our data support the idea
that hepatic effects of TH on gene regulation and metabolism are largely independent of Fgf21.

Materials and method
Mice
All animal experiments were approved by the Animal
Care and Use Committee of Houston Methodist Hospital
Research Institute. Mouse strains C57BL/6, ApoEK/K,
LdlrK/K, and TRbK/K were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA) at 9 weeks of age.
Fgf21K/K mice on a C57/BL6 background (Dutchak et al.
2012) were received from The University of Texas Southwestern Medical Center (Dallas, TX, USA). For short-term
ligand treatments (1 and 3 days) T3, GC1, or vehicle
(control) were administered to mice (nZ5) by oral gavage
at a dose of 1 mg/kg body weight, after which, mice were
killed and dissected for tissue harvesting. For long-term
treatments (2 weeks), GC1 was admixed into diet at a
dose of 0.8 mg/kg body weight, after which the mice were
killed for collection of blood and tissue samples.

Quantitative RT-PCR
Total RNA was isolated from livers or cultured cells using
the RNAeasy Kit (Qiagen) and reverse transcribed to cDNA
using the ABI Reverse Transcription Kit according to the
Published by Bioscientifica Ltd.
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manufacturer’s instructions. Gene transcript expression
was measured by quantitative RT-PCR (qPCR) (Roche
LightCycler 480 II), in 20 ml reactions that included
cDNA (10 ng of initial RNA input), 900 nM of each primer,
PCR-grade water, and 10 ml of 2! TaqMan Master Mix
(Applied Biosystems). The transcript expression levels
were normalized to peptidylprolyl isomerase A (PPIA)
expression levels. Independent samples were prepared
from five to six different mice per genotype or three
separate cell culture seedings and analyzed in technical
triplicates. Gene transcript abundance was assessed by
the standard DDCp method and results were expressed as
relative fold change compared with respective control
group. Primer catalog numbers are available on request.

Journal of Endocrinology

Serum FGF21 analyses
Mouse serum FGF21 concentrations were determined by
ELISA (Phoenix Secretomics (Burlingame, CA, USA), PS00101-EK-M-1), according to the manufacturer’s protocol.
Serum samples of six to seven mice from each treatment
were analyzed.

Immunoblot analysis
One hundred micrograms of liver were homogenized in
1 ml homogenization buffer (10 mM Tris–HCl (pH 7.5),
5 mM EDTA, 150 mM NaCl, 30 mM sodium phosphate,
10% glycerol, 0.5% NP40) containing complete protease
inhibitor cocktail (Roche) using a Polytron homogenizer.
The homogenate was centrifuged at 14 000 g for 8 min at
4 8C and the supernatant collected for further analysis.
The proteins were separated by SDS–PAGE, transferred
to polyvinylidine difluoride membranes (Millipore,
Billerica, MA, USA), and detected with primary FGF21
and b-actin (Sigma) antibodies at 1:1000 and 1:10 000
dilutions, respectively, and HRP-conjugated secondary
antibody at 1:5000 dilution. Immunoreactive proteins
were visualized using the ECL western blotting detection
system (Amersham, RPN2106), and densitometry analysis
was conducted with Scion Image v4.0.3.2 software.

Cell culture
HepG2 (ATCC, Bethesda, MD, USA) and HepG2-TRb
(Lin et al. 2013) cells were grown in DMEM supplemented
with 10% fetal bovine serum (FBS), 100 U/ml of penicillin,
0.1 g/l of streptomycin, and 4 mmol/l glutamine, under 95%
air and 5% CO2 at 37 8C. For cycloheximide (CHX) treatment,
HepG2-TRb cells were maintained within 10% resin-stripped
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0440
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FBS-DMEM media for 24 h before treatment. The cells were
pretreated with CHX at 10 mg/ml for 30 min, followed by
10 nM T3 incubation for 6 h, after which RNA was collected
using the RNAeasy Kit (Qiagen). For RNA interference assays,
HepG2-TRb cells were plated in 10% resin-stripped FBSDMEM media and grown to 50% confluency. The cells were
transfected with PPARa ON-TARGET plus SMART pool or
negative control siRNA (Dharmacon, Waltham, MA, USA)
at a 50 nM final concentration, and 48 h later treated with
10 nM T3 or bezofibrate for 6 h, after which RNA was collected using the RNAeasy Kit (Qiagen).

Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
using the EZ ChIP Kits (Millipore) according to the
manufacturer’s instructions. Briefly, mice livers were
homogenized with a hand-held homogenizer in PBS
containing a broad-spectrum protease inhibitor cocktail
and then cross-linked with 1% formaldehyde. The nuclei
were collected by adding lysis buffer following cross-linkage,
which was stopped through addition of glycine. The liver
nuclear solution was sonicated with a Fisher 60 Sonic
Dismembranator (Thermo Fisher Scientific, Waltham, MA,
USA). The sonicated solution was incubated with anti-TRb
polyclonal antibody or control rabbit IgG (Millipore) overnight with agitation at 4 8C. The TRb antibody used for ChIP
has also been used for TRb ChIP studies of mouse cerebellum
and liver (Dong et al. 2009, Paquette et al. 2011) and was
originally purchased from Affinity Bioreagents (Golden, CO,
USA), but was later made available through Thermo Fisher
Scientific and Pierce (Grand Island, NY, USA), as PA1-213A.
We have used the same antibody for western blotting analysis
of TRb expression in cell lines and mouse liver with
appropriate controls for TRb specificity shown (Ayers et al.
2014, Lammel Lindemann et al. 2014). Antibody-bound
chromatin was precipitated with protein G-conjugated
agarose beads, washed with gradient stringent buffers, and
eluted with the elution buffer provided with the kit. The
isolated DNA was analyzed by qPCR analysis using oligonucleotides corresponding to the following regions of the FGF21
locus: Fgf21C715/C902, forward: 5’-CAGACTGGCCCTCAGAGAAG-3’, reverse: 5’-CTCTGCCTAGGTTGGCATTC-3’.
Fgf21C3727/C3880 forward: 5’-CATGTGGATTCTGGGATTTG-3’, reverse: 5’-GACCAGGCTGGACTCAAGTT-3’.

Transient transfection
For cloning of Fgf21-luciferase reporters, a 339-bp fragment
of Fgf21 intron 2 was PCR amplified from C57BL/6 mouse
Published by Bioscientifica Ltd.
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Electrophoretic mobility shift assay (EMSA) was performed
by incubating 32P-labeled oligonucleotide probes with
in vitro translated TRb and RXRa. The results were
visualized by autoradiography. Competition assays were
performed by adding 100! molar excess of either
unlabeled oligonucleotide probes (specific competitor)
or unlabeled mutant oligonucleotide probe (nonspecific
competitor, mutated bases are indicated in each figure).
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Figure 1
Fgf21 is upregulated in livers of T3-treated mice. (A) Results of qRT-PCR
analysis of hepatic FGF21 transcript levels in WT (C57BL/6) mice treated
with T3 or GC1 for 24 h (nZ6/group) along with other secreted hepatic
factors, as follows: angiopoietin-like factors (ANGPTL) 3, 4, and 6;
angiotensinogen (AGT), hepatocyte growth factor (HGF), insulin-like
growth factor 1 (IGF1). (B) Hepatic Fgf21 mRNA levels in LDL receptor
knockout (LdlrK/K) and apolipoprotein E-knockout (ApoEK/K) mice
treated with T3 or GC1 for 24 h (nZ6/group). (C) Circulating levels of
FGF21 in LdlrK/K mice treated with T3 or GC1 for 24 h (nZ6/group).
(D) Hepatic Fgf21 mRNA levels in LdlrK/K mice 28 days following GC1
treatment (nZ6/group). Statistical significance of the observed changes is
denoted by single or double asterisks, which indicate and refers to P!0.05
or P!0.01 respectively.

gDNA and cloned into the BglII and HindIII sites of
pGL4-23. Positive clones were confirmed through sequencing. For luciferase assays, HepG2-TRb1 cells (2!105
cells/well) were seeded into six-well plates 12 h before
transfection of 1 mg/well of Fgf21-luciferase reporter
constructs and 0.1 mg/well of Renilla-luciferase control
plasmid using Fugene 6 transfection reagent. Twentyfour hours post transfection, cells were incubated with
10 nM T3 for another 24 h, after which luciferase activity
was determined using the Promega Dual Luciferase Assay
Kit following the manufacturer’s instructions.
http://joe.endocrinology-journals.org
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Microarray analysis
Mouse WG-6 v2 whole-genome expression arrays were
purchased from Illumina (San Diego, CA, USA), and cRNA
synthesis and labeling were performed using Illumina
TotalPrep-96 RNA Amplification Kit (Ambion, Austin, TX,
USA), with the labeling in vitro transcription reaction
performed at 37 8C for 14 h. Biotinylated cRNA samples
were hybridized to arrays at 58 8C for 18 h according to
the manufacturer’s protocol. Arrays were scanned using
BeadArray Reader (Illumina). Unmodified microarray data
obtained from GenomeStudio were background-subtracted
and quantile-normalized using the lumi package (Du et al.
2008) and analyzed with the limma package (Smyth 2005)
within R (R Development Core Team 2010). All analysis was
corrected for multiple hypotheses testing (Benjamini &
Hochberg 1995) and effects were determined to be significant when there was a greater than or equal to twofold
increase/decrease relative to the control and they had an
adjusted P value !0.05. Raw microarray data sets have been
deposited in the NCBI Gene Expression Omnibus (GEO)
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Figure 2
Fgf21 induction requires TRb. (A) qRT-PCR analysis of hepatic Fgf21
transcript levels in WT (C57BL/6) mice treated with T3 for 24 h or TrbK/K
knockout mice (nZ6/group). (B) Western blotting analysis of hepatic FGF21
protein levels in WT and TrbK/K mice with representative gel images at the
top and quantitation below. The statistical significance of the observed
changes is denoted by double asterisks, which indicate P!0.01.
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database under accession number GSE58062. Microarray
data was also validated through qPCR (TaqMan) analysis,
showing excellent correlation R2Z0.85 (nZ59).

Data analysis and statistics
All values are expressed as meanGS.E.M. Statistical analyses
were performed using GraphPad Prism Version 5.0
Software (GraphPad, Inc., San Diego, CA, USA). Data were
analyzed by Student’s t-test, Mann–Whitney U test, or
one-way ANOVA, where P values !0.05 were considered
to be statistically significant.

Serum metabolites
Serum aliquots were sent to the comparative pathology
laboratory of Baylor College of Medicine (Houston, TX,
USA) for serum chemistry analysis.
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thyromimetic GC1 also elicited increases in hepatic Fgf21
expression, which persisted for at least 2 weeks with
continuous treatment (Fig. 1D). Optimal hepatic T3
induction of FGF21 required TRb, the predominant TR
subtype in liver (Fig. 2A and B). Thus, T3 acts primarily
through TRb to induce hepatic Fgf21 expression.

TRb directly induces Fgf21 in cultured cells
To define the mechanisms of TH-dependent induction of
hepatic Fgf21 expression, we examined the response of Fgf21
mRNA to T3 or GC1 in human HepG2 cells that stably express
TRb (Lin et al. 2013). We observed induction of FGF21
following short-term treatment with either ligand (Fig. 3A).
This effect persisted over several time points (Fig. 3B and
A

C
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FGF21

We examined the effects of acute (24 h) treatment of
male C57BL/6 mice with T3 or the thyromimetic GC1 on
hepatic Fgf21 expression. Fgf21 mRNA was induced by
both ligands, an effect not observed for genes that encode
other secreted hepatic factors (Fig. 1A). Similar effects of
TR ligands on Fgf21 expression were seen in two mouse
models of dyslipidemia (ApoEK/K and LdlrK/K) (Fig. 1B)
and FGF21 induction was accompanied by increases in
circulating FGF21 peptide in serum (Fig. 1C). The selective

1.2

were pretreated with CHX for 30 min, followed by T3 for 6 h. (E) PPARa
knockdown does not affect T3 response of FGF21 in HepG2 cells. qRT-PCR
analysis of FGF21 transcript levels after treatment of HepG2-TRb cells with
bezofibrate or T3 for 2 h. Results are shown in the presence of control
scrambled siRNA or PPARa-specific siRNA. Knockdown levels of PPARa
transcripts are shown in the inset. The statistical significance of the
observed changes is denoted by single or double asterisks, which indicate
P!0.05 and P!0.01 respectively.
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Figure 3
TRb-dependent induction of FGF21 in cultured cells. (A) FGF21 mRNA levels
in HepG2 cells treated with GC1 (10 nM), T3 (10 nM) or vehicle for 24 h
(nZ4). (B) Expression levels of FGF21 mRNA in HepG2 cells that express
exogenous TRb1 or in parental HepG2 cells examined by RT-qPCR at
different time points after T3 induction (nZ4). (C) T3 concentration
dependence of induction of FGF21 mRNA in HepG2 cells that expressed
exogenous TRb was examined by RT-qPCR for various concentrations of T3
for 24 h (nZ4). (D) T3 induction of FGF21 mRNA is insensitive to CHX. Cells
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Figure 4
A TRb-binding site in the FGF21 second intron. (A) Results of ChIP-Seq analysis
with HepG2-TRb cells showing binding events in the FGF21 second intron. (B)
Representative gel showing results of ChIP analysis with an anti-TRb1 antibody
to verify binding within FGF21 intron 2 along with an IgG control. (C) qRT-PCR
analysis of ChIP experiments showing specific binding of TRb1 to the FGF21
intron 2 in native mouse liver. Immunoprecipitations were carried out with
either TRb antibodies or control IgG, and immunopurified DNA was analyzed
with primers flanking intron 2 of FGF21 (C715 to 902) or a control region
(C3727 to C3880) (nZ4). The statistical significance of the observed changes
is denoted by double asterisks, which indicate P!0.01.
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results not shown). A modest T3 response was also observed in
parental HepG2 cells after extended T3 treatment (Fig. 3B);
this delayed effect resembles the kinetics of T3 induction of
other bona fide hepatic TR-target genes in this cell type and is
probably a consequence of low levels of TRb that are present
in these cells (Yuan et al. 2012). T3-dependent FGF21
induction exhibited classical dose dependence with maximal
activation with 10 nM hormone (Fig. 3C), implying that
this T3 effect was TR-dependent, and was maintained after
pretreatment with the protein synthesis inhibitor CHX,
implying a direct transcriptional effect of TR (Fig. 3D).
Interestingly, the effects of TRb on FGF21 expression were
A
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294

not absolutely dependent on PPARa in HepG2 (Fig. 3E).
Although induction of Fgf21 mRNA by the PPARa ligand
bezofibrate was abrogated by a PPARa-specific siRNA that
reduced PPARa transcript levels by 80% (inset), the T3
response was unaffected.

A functional TRE in the Fgf21 second intron
To determine whether TRb might bind the Fgf21 locus
independently of PPARa, we consulted a published
ChIP-chip dataset and our own preliminary ChIP-Seq
results. Results of recent studies have indicated the
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Figure 5
An intronic TRE in the FGF21 locus. (A) Reporter assays were performed in
HepG2-TRb1 cells co-transfected with a reporter construct harboring intron 2
of FGF21 in the presence of PPARa or TRb expression plasmid. The cells were
treated with either 100 nM WY14643 or 10 nM T3 (nZ4). (B) As shown in
Fig. 5A, results of luciferase assays performed with a variety of reporter
genes bearing intron 2 truncations are shown in the schematic diagram.
(C) Diagrammatic representation of the FGF21 promoter within the reporter
vector (the region that displayed enrichment within the ChIP-assay). The
FGF21 promoter used in our studies contains binding sites for TRb. The TRE
determined to mediate the TRb-response is also shown, as indicated by
truncation and mutant analysis. (D) As shown in Fig. 5A, HepG2-TRb1 cells
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co-transfected with a reporter construct harboring intron 2 of FGF21 or
TRE-mutant reporter constructs or control vector pGL4 in the presence of TRb
expression plasmid. The cells were treated with either vehicle or 10 nM T3
(nZ4). (E) Electrophoretic mobility shift assay (EMSA) depicting TRb binding to
the discovered TRE. The response elements were measured by mixing 100 ng
of purified TRb (DBD–LBD) with 1 pM of biotin-labeled double-stranded
oligonucleotide corresponding to C715 to C1054 of FGF21. Binding
specificity of the regulatory region was verified with competition experiments
in which 50-fold molar excess of unlabeled C715/C1054 oligomer or mutantTRE C715/C1054 oligomer (nZ4). The statistical significance of the observed
changes is denoted by double asterisks, which indicate P!0.01.
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presence of an intronic TRb-binding peak within the Fgf21
locus in mouse cerebellum (Dong et al. 2009) and we later
confirmed the existence of this peak in the data derived
from our own ChIP-Seq analysis of TRb-binding events in
HepG2 cells (Fig. 4A) (Ayers et al. 2014). We verified TRb
binding at this location with conventional ChIP-PCR
performed on human HepG2-TRb cells (Fig. 4B) and on
native mouse liver (Fig. 4C).
Cloned sequences corresponding to the second intron
of human FGF21 conferred T3 responsiveness upon a
luciferase reporter (Fig. 5A). There was no response to
PPARa ligand (WY14643). Deletion mapping indicated
that important T3-responsive elements lay between the
intronic sequences C771 and C842 downstream of the
Fgf21 transcriptional start site (Fig. 5B). This region of
the mouse gene harbored a degenerate nonconsensus TRE
(DR-5) with one well conserved half site (AGGTCA; reverse
strand TCCAGT) (Fig. 5C). Mutation of the putative TRE
blocked the responses to T3 of the Fgf21-dependent
luciferase reporter (Fig. 5D). Furthermore, the putative
TRE bound bacterially expressed TRb in EMSA and this
interaction was abolished by mutation of the AGGTCA
sequence or an excess of WT oligonucleotide (Fig. 5E).
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Altered hepatic T3-responses in Fgf21

K/K

As T3 induces FGF21 in liver, and secreted FGF21 peptide may
exert autocrine/paracrine effects upon gene expression in
hepatocytes, we determined whether T3 regulated the same
genes in the livers of WT and euthyroid Fgf21K/K mice using
Illumina BeadArray analysis. More than 500 gene transcripts
displayed significant response (greater than or equal to
twofold with and adjusted P value !0.05) to a 3-day T3
treatment in WT mice, in accordance with previous studies.
In general, T3-dependent gene regulation patterns were
similar in both WT and Fgf21-knockout mice and the
majority of T3 responses differed by not more than 50%
(black points located within the dotted lines that delimit a
twofold difference between WT and Fgf21K/K mice) (Fig. 6A).
We detected two clusters of genes with altered T3
response in the Fgf21K/K background (red points, outside
of dotted delimiting lines). One group (Table 1, 31 genes)
exhibited diminished T3-dependent activation in the
Fgf21 K/K background, and the other altered group
(Table 2, 23 genes) displayed diminished T3-dependent
repression. These altered responses to T3 were readily
reproduced in independent high-throughput qRT-PCR
experiments (Fig. 6B). Examples of such genes with
diminished responses to T3 in the Fgf21-knockout mice
include Dio1, Insig2, Cdkn1, and Glut1 (Fig. 6C, full gene
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0440
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Figure 6
Similar patterns of T3 responses in WT and Fgf21-knockout mice. (A) Scatter
plots of T3 responses in livers of WT and Fgf21-knockout mice treated
with T3 for 3 days. Dots represent genes that were induced or repressed at
least twofold by T3 treatment with an adjusted P value of !0.05. Dotted
lines represent a twofold deviation from WT values. (B) qPCR validation of
the microarray data. R2Z0.85 (nZ59). (C) Representative qPCR verification
of genes that display diminished responses to T3 in the Fgf21K/K
background. (D) Representative qPCR verification of genes that display
unchanged responses to T3 in the Fgf21K/K background. The statistical
significance of the observed changes is denoted by single or double
asterisks, which indicate P!0.05 and P!0.01 respectively.

names in Table 1). Genes that displayed similar levels of T3
response in both strains include Cpne2, Rab34, Creld2, and
Wfdc6, as identified in our previous studies (Lin et al. 2013)
(Fig. 6D). Thus, targeted ablation of Fgf21 in the mouse
germ line did not result in the global inhibition of a large
percentage of hepatic T3 responses, but FGF21 was required
for induction of a small subset of T3-regulated genes.
We could not perceive many obvious relationships
between genes that display altered responses to T3 in the
Fgf21-knockout mice and canonical hepatic metabolic
process regulated by TH (Tables 1, 2, and 3). Results of
ingenuity pathway analysis (IPA) indicated that the gene
subsets that showed altered T3 response in the Fgf21knockout background might affect the action of vitamin C,
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Probe_ID

Symbol

Entrez gene name

ILMN_2874352
ILMN_2647234
ILMN_2813830
ILMN_3009501
ILMN_1241350

Cyp17A1
Dio1
Nt5e
Kcnk1
Vsig4

ILMN_1239959
ILMN_2619620

E030018b13rik
C1qb

ILMN_2715840

C1qc

ILMN_2775030
ILMN_2528155

Folr2
Loc227995

ILMN_2878071
ILMN_1234858
ILMN_2671923
ILMN_1252636

Lyz1/Lyz2
Insig2
Ly86
Mmd2

ILMN_2925653

Ear2

ILMN_2634083

Cdkn1a

ILMN_1216880

Emr1

ILMN_2640346

P2ry13

ILMN_2785648
ILMN_2533376
ILMN_2752524

Cd207
Mmp27
Paqr9

ILMN_2524986

Ear3

ILMN_2948296
ILMN_2819319
ILMN_1241695

Wfdc12
Rrm2
Ms4a6a

ILMN_2896170
ILMN_3118707
ILMN_2548010
ILMN_2788073
ILMN_2761585
ILMN_2728300
ILMN_1258159

Apcs
Sla
Hopx
Hmox1
2400009b08RIK
Mdm1
Glut1

Cytochrome P450, family 17, subfamily A
Deiodinase, iodothyronine, type I
5 0 -nucleotidase, ecto (CD73)
Potassium channel, subfamily K, member 1
V-set and immunoglobulin domain
containing 4
RIKEN cDNA E030018B13 gene
Complement component 1, q
subcomponent, B chain
Complement component 1, q
subcomponent, C chain
Folate receptor 2 (fetal)
Predicted gene 13607, actin-like
6A pseudogene
Lysozyme 2
Insulin-induced gene 2
Lymphocyte antigen 86
Monocyte to macrophage differentiationassociated 2
Eosinophil-associated, ribonuclease A
family, # 2
Cyclin-dependent kinase inhibitor 1A
(p21, CIP1)
EGF-like module containing, mucin-like,
hormone receptor-like 1
Purinergic receptor P2Y,
G-protein-coupled, 13
CD207 molecule, langerin
Matrix metallopeptidase 27
Progestin and adipoQ receptor family
member IX
Eosinophil-associated, ribonuclease A
family, #3
WAP four-disulfide core domain 12
Ribonucleotide reductase M2
Membrane-spanning 4-domains,
subfamily A, member 6A
Amyloid P component, serum
Src-like-adaptor
HOP homeobox
Heme oxygenase (decycling) 1
RIKEN cDNA 2400009B08 gene
Mdm1 nuclear protein homolog (mice)
Glucose transporter 1

the complement pathway, and other processes (Table 3 and
results not shown). Similar biological functions were
predicted through Genecodis analysis (Tabas-Madrid et al.
2012) (not shown). More directed queries in which we
utilized IPA function pathway analysis to probe for the
association of defined hepatic metabolic pathways with the
T3/FGF21-dependent gene subset revealed the connections
of several members of this gene set with different aspects of
lipid metabolism, amino acid metabolism, and carbohydrate
metabolism (Table 4). Inspection of these relationships did
not allow us to generate many obvious predictions about the
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0440
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WT

Fgf21KO

Adjusted P value
WT

Fgf21KO

8.861
8.268
7.634
7.393
6.151

3.110
3.229
2.870
3.370
1.941

0.000
0.023
0.001
0.003
0.016

0.029
0.227
0.060
0.050
0.420

6.088
6.041

K1.005
1.988

0.020
0.010

0.998
0.343

5.785

1.596

0.009

0.540

5.643
5.618

2.751
2.070

0.002
0.021

0.039
0.368

5.506
5.022
4.760
4.749

2.081
1.302
1.954
1.231

0.009
0.035
0.004
0.011

0.265
0.830
0.185
0.824

4.691

1.715

0.025

0.499

4.595

1.083

0.013

0.947

4.462

1.711

0.022

0.466

4.249

2.000

0.005

0.158

4.242
4.132
3.988

1.781
1.960
1.724

0.006
0.025
0.045

0.260
0.319
0.505

3.869

1.493

0.028

0.599

3.706
3.687
3.376

1.438
1.627
1.641

0.020
0.000
0.020

0.601
0.100
0.380

3.291
3.113
2.970
2.882
2.409
2.386
1.580

1.301
1.191
1.422
1.411
1.109
1.185
1.087

0.043
0.023
0.016
0.005
0.020
0.003
0.041

0.761
0.824
0.491
0.357
0.870
0.597
0.870

influences of these genes upon local hepatic and systemic
metabolism (see ‘Discussion’).
Given that there were weak associations of the
T3/FGF21-dependent gene set with classical T3-dependent
hepatic metabolic pathways, we determined whether
Fgf21-knockout influenced the levels of serum metabolites
under the conditions of our experiment (Fig. 7). Previously,
treatment with T3 and a thyromimetic has been shown to
result in rapid reductions in serum cholesterol levels in WT
mice (Lin et al. 2012, Lammel Lindemann et al. 2014).
While we were able to reproduce this effect with short T3
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Negatively T3-regulated genes influenced by Fgf21 knockout
Fold change
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Probe_ID

Symbol

Entrez gene name

ILMN_2852624
ILMN_1253233
ILMN_2976211

Hamp/Hamp2
Dsg1c
Cyp2b23

ILMN_2796472
ILMN_1232758
ILMN_1214219
ILMN_1230145
ILMN_2565942
ILMN_1256423
ILMN_1218441
ILMN_2875737

Vldlr
Gm3065
Col27a1
Acvr2b
Flnb
Ranbp3l
Slc23a3
Cyp2d6

ILMN_2523012
ILMN_2625233
ILMN_1213804
ILMN_2624328

Meg3
9130230l23rik
Lrp4
Adamts7

ILMN_1239872
ILMN_1227319
ILMN_1247135
ILMN_2764325
ILMN_2587761
ILMN_2954098
ILMN_2718600
ILMN_2622891

5830473c10rik
Vwce
Znf276
Bricd5
Kif1b
Lgals6
Nfyb
C12orf43

Hepcidin antimicrobial peptide
Desmoglein 1 gamma
Cytochrome P450, family 2, subfamily b,
polypeptide 23
Very-LDL receptor
Predicted gene 3065
Collagen, type XXVII, alpha 1
Activin A receptor, type IIB
Filamin B, beta
RAN-binding protein 3-like
Solute carrier family 23, member 3
Cytochrome P450, family 2, subfamily D,
polypeptide 6
Maternally expressed 3
RIKEN cDNA 9130230L23 gene
LDL receptor-related protein 4
ADAM metallopeptidase with thrombospondin type 1 motif, 7
RIKEN cDNA 5830473C10 gene
Von Willebrand factor C and EGF domains
Zinc finger protein 276
BRICHOS domain containing 5
Kinesin family member 1B
Lectin, galactose-binding, soluble 6
Nuclear transcription factor Y, beta
Chromosome 12 open reading frame 43

treatments (Fig. 7A), it was unaltered in the Fgf21-knockout
background. No T3- or Fgf21-dependent changes in serum
triglyceride or glucose levels were detected during the
course of this treatment (Fig. 7B and C).

Discussion
PPARa-dependent induction of FGF21 is required for
changes in expression of genes that are involved in the
fasting response in liver, and secreted hepatic Fgf21
influences local hepatocyte metabolism and communicates information from liver to other tissues to coordinate
fasting responses. Thus, FGF21 has attracted attention as
a possible therapeutic to modulate metabolic disease. In
this study, we verified previous observations which
indicate that T3 induces hepatic FGF21 production
(Adams et al. 2010, Domouzoglou et al. 2014), and further
dissected the mechanism of this effect and tested the
possibility that FGF21 is required for T3-dependent
changes in local hepatic T3 responses. Our results therefore
support the concept that T3 and FGF21 signaling pathways
exhibit mutual regulatory dependence, but function
largely independently (Domouzoglou et al. 2014).
T3 acts through TRb to directly induce FGF21 expression. We extended previous studies (Adams et al. 2010,
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0440
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Adjusted P value

WT

Fgf21KO

WT

Fgf21KO

K11.73
K8.159
K7.294

K5.569
K3.932
1.075

0.006
0.002
0.022

0.049
0.029
0.970

K7.191
K4.219
K3.491
K3.352
K3.277
K3.274
K3.073
K2.945

K2.436
K1.550
K1.564
K1.575
K1.451
K1.440
K1.479
K1.313

0.011
0.010
0.001
0.032
0.038
0.009
0.030
0.022

0.253
0.480
0.189
0.488
0.605
0.452
0.519
0.655

K2.936
K2.890
K2.767
K2.635

K1.143
K1.395
K1.030
K1.154

0.033
0.026
0.020
0.002

0.879
0.559
0.975
0.713

K2.597
K2.440
K2.209
K2.202
K2.135
K2.065
K2.061
K2.059

K1.026
K1.212
K1.095
K1.089
K1.021
K1.024
K1.027
K1.028

0.011
0.011
0.007
0.036
0.033
0.011
0.005
0.044

0.975
0.662
0.838
0.902
0.980
0.969
0.956
0.973

Domouzoglou et al. 2014) to show that sustained
TR-dependent induction of FGF21 is elicited by a selective
TRb modulator and is dependent on TRb. Furthermore,
similar effects were also observed in a human liver cell
line (HepG2), in which FGF21 induction was amplified in
the presence of exogenous TRb1, and T3-dependent
induction of FGF21 was also detectable in the presence
of low endogenous levels of TRb1 in this cell type (Yuan
et al. 2012). Thus, the capacity for T3 regulation of hepatic
FGF21 production is conserved in humans and in cultured
cells of hepatic origin. Finally, TR regulation of FGF21

Table 3

IPA canonical pathway analysis of T3/FGF21-dependent

genes
Ingenuity canonical
pathways

Klog
(P value)

Ratio

Molecules

Antioxidant action
of vitamin C

2.89

0.027

Complement system
Phospholipases
Bladder cancer
signaling
Pancreatic adenocarcinoma signaling

2.61
2.14
1.77

0.057
0.030
0.021

HMOX1,
SLC23A3,
PLA2G7
C1QC, C1QB
HMOX1, PLA2G7
MMP27, CDKN1A

1.62

0.016

HMOX1, CDKN1A
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IPA function pathway analysis of metabolic pathway association with T3/FGF21-dependent genes

Function and pathway

Lipid Metabolism
Concentration of cholesterol
Efflux of cholesterol
Accumulation of triacylglycerol
Conversion of lipid
Quantity of steroid
Amino acid metabolism
Carbohydrate metabolism
Insulin-dependent diabetes mellitus

Journal of Endocrinology

and others

Number of molecules

P value

Molecules

4
2
2
3
5
2
3
6

0.0051
0.0192
0.0139
0.0053
0.0067
0.0030
0.0037
0.0012

Cdkn1a, Dio1, P2ry13, Vldlr
Apcs, Vldlr
Insig2, Vldlr
Cyp17a1, Cyp2d6, Hmox1
Cdkn1a, Cyp17a1, Dio1, P2ry13, Vldlr
Cdkn1a, Dio1
Lyz1/Lyz2, Nt5e, Pla2g7
Col27a1, Ly86, Lyz1/Lyz2, Ms4a6a, Nt5e, P2ry13

exhibits an appropriate T3 dose response and is not
affected by the protein synthesis inhibitor CHX, implying
a direct effect of T3 through TRs.
While TRs do not bind to the Fgf21 proximal promoter,
the results of studies by our own group and others indicate
that TREs are often located within introns or the
3 0 downstream region of target genes (Chatonnet et al.
2013, Gagne et al. 2013, Ayers et al. 2014, Ramadoss et al.
2014). We therefore searched published databases of
TRE localization and noted that the mouse Fgf21 locus
harbors a TR-binding site in intron 2. This binding site
was first detected in a study of TR-binding events near
of T3-target genes in cerebellum (Dong et al. 2009), which
we later confirmed by our own genome wide assessment
of TRb1-binding events that utilized an engineered
human HepG2 cell line that expresses exogenous TRb1
(Ayers et al. 2014). We verified TR localization with human
and mouse intron 2 using traditional ChIP-PCR approaches
in HepG2 and native mouse liver and identified a
functional TRE in this region of the mouse gene. We
therefore suggest that TRs act through this intronic TRE
to activate FGF21 expression in HepG2 cells and that
this effect is independent of PPARa signaling.
While our results indicate that TR can bind to a
functional TRE in FGF21 intron 2, we emphasize that they
do not contradict the results of previous studies which
indicate that TRs cooperate with PPARa to enhance FGF21
proximal promoter activity (Adams et al. 2010). Unlike the
FGF21 proximal promoter, the putative FGF21 intronic
TRE does not respond to PPARa ligands. Furthermore,
bezofibrate activation of the human FGF21 gene is
abolished by PPARa knockdown in HepG2 cells, with the
T3 response unaffected by PPARa knockdown. Thus, T3 can
activate the FGF21 gene independently of PPARa.
However, we also verified that TRb and PPARa cooperate
to elicit additive increases in FGF21-promoter-dependent
luciferase reporter activity in transient transfections
(results not shown). In the light of this study (Adams
http://joe.endocrinology-journals.org
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et al. 2010) and other suggestions that TRs cooperate with
PPARs to regulate gene expression (Lu & Cheng 2010),
we suspect that TRs bound to the downstream intronic
TRE can communicate with PPARa to regulate FGF21
expression. This idea leads to the prediction that T3
regulation of FGF21 could be influenced by changes in
PPARa activity and it will be interesting to see whether
dietary conditions or administration of PPARa ligands
could alter the patterns of hepatic T3 regulation of FGF21
or hepatic gene response in general.
As FGF21 acts in an autocrine/paracrine fashion to
regulate hepatic target genes involved in metabolic
responses (Inagaki et al. 2007), we also tested the hypothesis
that T3-dependent regulation of hepatic gene expression
programs would require FGF21. Specifically, we used an
unbiased approach to determine whether responses to T3 of
any hepatic genes was diminished or abrogated in a mouse
strain with a targeted deletion of the Fgf21 gene locus. While
T3 regulates hundreds of genes in the livers of euthyroid
mice, many with important roles in T3-regulation of
metabolic responses, there were limited differences in T3
response patterns in WT and Fgf21K/K mice. During our
studies, a group led by Maratos-Flier et al. examined T3
A

C

B
180

Concentration in serum
(mg/dl)
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T3

160

Triglyceride

450

Glucose

120
300

120
80
60

**

**
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40
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0
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FGF21–/–
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Figure 7
Analysis of serum metabolites in WT and Fgf21-knockout mice. (A) total
serum cholesterol, (B) triglycerides, (C) glucose in WT and Fgf21K/K mice
after 3-day T3 treatment. The statistical significance of the observed
changes is denoted by double asterisks, which indicate P!0.01.
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regulation of metabolic parameters in Fgf21-knockout mice
and the effects of administered FGF21 in hypothyroid and
euthyroid mouse backgrounds (Domouzoglou et al. 2014).
Results of this study revealed that T3 and FGF21-dependent
effects upon serum and hepatic lipid levels, thermogenesis
and energy metabolism, and selected T3 and FGF21 target
genes are almost completely independent of the other
hormone signaling system. Our transcriptome-wide gene
expression studies extend and lend further support to this
idea, and moreover, our own investigation of the effects of
FGF21 and T3 upon the levels of serum metabolites confirms
that T3-dependent reductions in total serum cholesterol are
completely independent of FGF21.
We detected a small subset of hepatic genes that
displayed diminished responses to T3 in the Fgf21K/K
background. In principle, such genes could be indirect
targets that lie downstream of the FGF21 peptide, or FGF21
could be a permissive factor for induction of direct TR
targets, analogous to the hepatic PPARa/FGF21 feedforward loop established under fasting conditions in
which FGF21 activation prolongs PPARa-dependent
responses (Badman et al. 2007, Inagaki et al. 2007). While
we have not determined the mechanisms of these effects,
we suspect that the latter mechanism is at play at least in
regulation of Dio1, which contains bona fide TREs within
its proximal promoter (Zhang et al. 1998). Perhaps more
surprising, however, was that T3/FGF21-dependent genes
were associated with complement activation and the cell
cycle and that many classical T3-regulated genes involved
in cholesterol metabolism (Lin et al. 2012, Lammel
Lindemann et al. 2014), fatty acid synthesis, b-oxidation,
and gluconeogenesis (Singh et al. 2013, Suh et al. 2013,
Thakran et al. 2013) did not appear in this list. The
significance of the dual T3/FGF21 dependency displayed
by this gene subset is not clear and requires further
investigation.
We recognize that the notion that T3 and FGF21
regulate hepatic metabolic response independently of
each other must remain qualified for several reasons.
We analyzed T3-dependent changes in gene expression
and serum lipid parameters after 72 h treatment. While
this is long enough to obtain significant elevations of
hepatic and serum FGF21 levels, it is possible that
interactions between TR and FGF21-dependent pathways
could emerge over longer treatment times. Furthermore,
our studies were performed in euthyroid mice treated
with T3 and not hypothyroid mice. Thus, it is possible
that some T3- and FGF21-responsive genes with key
roles in metabolic response could be fully induced at T3
concentrations observed in euthyroid mice (data shown
http://joe.endocrinology-journals.org
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in Lin et al. (2013)). Arguing against these possibilities,
however, is the failure of the Maratos-Flier group also to
identify defects in TR-dependent changes in metabolic
parameters and gene expression in FGF21 knockouts
over time courses of more than 1 week and in hypothyroid mice with varying levels of T3 (Domouzoglou
et al. 2014).
It also remains possible that some members of the
T3/FGF21-responsive gene subset could exert hard to predict
effects upon metabolic responses. We attempted a more
exhaustive effort to define the association of the T3/FGF21responsive gene subset with classical metabolic pathways
and discovered possible association of genes with various
aspects of lipid, amino acid, and carbohydrate metabolic
pathways and insulin-dependent diabetes mellitus (Table 4).
For example, DIO1 encodes a product that catalyzes the
conversion of T4 to T3 and therefore will alter local TH levels
and, potentially, TR actions upon key genes involved in
cholesterol metabolism. INSIG2 is an inhibitor of sterol
response element-binding protein (SREBP) activation and
changes in levels of this transcription factor could result
in widespread secondary alterations in the expression
patterns of genes that regulate lipid metabolism. While it
is conceivable that altered cooperation of TH and FGF21 at
these, and other, genes could ultimately result in changes
in systemic cholesterol and lipid levels, such effects were
not obvious over the course of our study (Fig. 7). At present
our results are most consistent with the notion that T3dependent hepatic gene regulation patterns are largely
independent of FGF21 signaling.

Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by NIH RC4 DK090849 (P W) and National Natural
Science Foundation of China No. 81270868 (X X).

Author contribution statement
X X and P W designed the experiments; A Z, J P Y, J H S and S D A performed
the research; G E W, D H S, A K, C P and P Z contributed reagents/analytical
tools and; analyzed data; and X X and P W wrote the paper.

Acknowledgements
The authors wish to honor the memory of John D Baxter (deceased) whose
insights into thyroid hormone inspired this study. They thank Dr Steven A
Kliewer who provided us the FGF21-knockout mice for this study.

Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 07/04/2022 03:50:28PM
via free access

Research

A ZHANG

and others

Journal of Endocrinology

References
Adams AC, Astapova I, Fisher FM, Badman MK, Kurgansky KE, Flier JS,
Hollenberg AN & Maratos-Flier E 2010 Thyroid hormone regulates
hepatic expression of fibroblast growth factor 21 in a PPARadependent manner. Journal of Biological Chemistry 285 14078–14082.
(doi:10.1074/jbc.C110.107375)
Ayers S, Switnicki MP, Angajala A, Lammel J, Arumanayagam AS & Webb P
2014 Genome-wide binding patterns of thyroid hormone receptor b.
PLoS ONE 9 e81186. (doi:10.1371/journal.pone.0081186)
Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS & Maratos-Flier E
2007 Hepatic fibroblast growth factor 21 is regulated by PPARa and
is a key mediator of hepatic lipid metabolism in ketotic states.
Cell Metabolism 5 426–437. (doi:10.1016/j.cmet.2007.05.002)
Baxter JD & Webb P 2009 Thyroid hormone mimetics: potential
applications in atherosclerosis, obesity and type 2 diabetes.
Nature Reviews. Drug Discovery 8 308–320. (doi:10.1038/nrd2830)
Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate:
a practical and powerful approach to multiple testing. Journal of
the Royal Statistical Society. Series B (Methodological) 57 289–300.
(doi:10.2307/2346101)
Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB,
Kharitonenkov A & Wasserman DH 2009 Fibroblast growth
factor 21 controls glycemia via regulation of hepatic glucose flux
and insulin sensitivity. Endocrinology 150 4084–4093. (doi:10.1210/
en.2009-0221)
Chatonnet F, Guyot R, Benoit G & Flamant F 2013 Genome-wide analysis
of thyroid hormone receptors shared and specific functions in neural
cells. PNAS 110 E766–E775. (doi:10.1073/pnas.1210626110)
Cheng SY, Leonard JL & Davis PJ 2010 Molecular aspects of thyroid
hormone actions. Endocrine Reviews 31 139–170. (doi:10.1210/
er.2009-0007)
Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE
& Kharitonenkov A 2008 Fibroblast growth factor 21 corrects obesity
in mice. Endocrinology 149 6018–6027. (doi:10.1210/en.2008-0816)
Domouzoglou EM & Maratos-Flier E 2011 Fibroblast growth factor 21 is
a metabolic regulator that plays a role in the adaptation to ketosis.
American Journal of Clinical Nutrition 93 901S–905S. (doi:10.3945/ajcn.
110.001941)
Domouzoglou EM, Fisher FM, Astapova I, Fox EC, Kharitonenkov A, Flier JS,
Hollenberg AN & Maratos-Flier E 2014 Fibroblast growth factor 21
and thyroid hormone show mutual regulatory dependency but
have independent actions in vivo. Endocrinology 155 2031–2040.
(doi:10.1210/en.2013-1902)
Dong H, Yauk CL, Rowan-Carroll A, You SH, Zoeller RT, Lambert I &
Wade MG 2009 Identification of thyroid hormone receptor binding
sites and target genes using ChIP-on-chip in developing mouse
cerebellum. PLoS ONE 4 e4610. (doi:10.1371/journal.pone.0004610)
Du P, Kibbe WA & Lin SM 2008 lumi: a pipeline for processing Illumina
microarray. Bioinformatics 24 1547–1548. (doi:10.1093/bioinformatics/
btn224)
Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ &
Kliewer SA 2012 Fibroblast growth factor-21 regulates PPARg activity
and the antidiabetic actions of thiazolidinediones. Cell 148 556–567.
(doi:10.1016/j.cell.2011.11.062)
Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R,
Mohammadi M, Kuro-o M, Mangelsdorf DJ et al. 2010 Research
resource: comprehensive expression atlas of the fibroblast growth
factor system in adult mouse. Molecular Endocrinology 24 2050–2064.
(doi:10.1210/me.2010-0142)
Gagne R, Green JR, Dong H, Wade MG & Yauk CL 2013 Identification
of thyroid hormone receptor binding sites in developing mouse
cerebellum. BMC Genomics 14 341. (doi:10.1186/1471-2164-14-341)
Iglesias P, Selgas R, Romero S & Diez JJ 2012 Biological role, clinical
significance, and therapeutic possibilities of the recently discovered

http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0440

Ñ 2015 Society for Endocrinology
Printed in Great Britain

Thyroid hormone/FGF21
interactions

224:3

300

metabolic hormone fibroblastic growth factor 21. European Journal of
Endocrinology 167 301–309. (doi:10.1530/EJE-12-0357)
Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y,
Goetz R, Mohammadi M, Esser V et al. 2007 Endocrine regulation
of the fasting response by PPARa-mediated induction of fibroblast
growth factor 21. Cell Metabolism 5 415–425. (doi:10.1016/j.cmet.
2007.05.003)
Johnson CL, Weston JY, Chadi SA, Fazio EN, Huff MW, Kharitonenkov A,
Koester A & Pin CL 2009 Fibroblast growth factor 21 reduces the
severity of cerulein-induced pancreatitis in mice. Gastroenterology
137 1795–1804. (doi:10.1053/j.gastro.2009.07.064)
Kliewer SA & Mangelsdorf DJ 2010 Fibroblast growth factor 21: from
pharmacology to physiology. American Journal of Clinical Nutrition
91 254S–257S. (doi:10.3945/ajcn.2009.28449B)
Lammel Lindemann JA, Angajala A, Engler DA, Webb P & Ayers SD 2014
Thyroid hormone induction of human cholesterol 7a-hydroxylase
(Cyp7a1) in vitro. Molecular and Cellular Endocrinology 388 32–40.
(doi:10.1016/j.mce.2014.02.003)
Lin JZ, Martagon AJ, Hsueh WA, Baxter JD, Gustafsson JA, Webb P &
Phillips KJ 2012 Thyroid hormone receptor agonists reduce serum
cholesterol independent of the LDL receptor. Endocrinology 153
6136–6144. (doi:10.1210/en.2011-2081)
Lin JZ, Sieglaff DH, Yuan C, Su J, Arumanayagam AS, Firouzbakht S,
Cantu Pompa JJ, Reynolds FD, Zhou X, Cvoro A et al. 2013 Gene specific
actions of thyroid hormone receptor subtypes. PLoS ONE 8 e52407.
(doi:10.1371/journal.pone.0052407)
Lu C & Cheng SY 2010 Thyroid hormone receptors regulate adipogenesis
and carcinogenesis via crosstalk signaling with peroxisome proliferatoractivated receptors. Journal of Molecular Endocrinology 44 143–154.
(doi:10.1677/JME-09-0107)
Paquette MA, Dong H, Gagne R, Williams A, Malowany M, Wade MG &
Yauk CL 2011 Thyroid hormone-regulated gene expression in juvenile
mouse liver: identification of thyroid response elements using
microarray profiling and in silico analyses. BMC Genomics 12 634.
(doi:10.1186/1471-2164-12-634)
Ramadoss P, Abraham BJ, Tsai L, Zhou Y, Costa-e-Sousa RH, Ye F, Bilban M,
Zhao K & Hollenberg AN 2014 Novel mechanism of positive
versus negative regulation by thyroid hormone receptor b1 (TRb1)
identified by genome-wide profiling of binding sites in mouse liver.
Journal of Biological Chemistry 289 1313–1328. (doi:10.1074/jbc.
M113.521450)
R Development Core Team 2010 R: A language and environment for
statistical computing. R Foundation for Statistical Computing,
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
Singh BK, Sinha RA, Zhou J, Xie SY, You SH, Gauthier K & Yen PM 2013
FoxO1 deacetylation regulates thyroid hormone-induced transcription
of key hepatic gluconeogenic genes. Journal of Biological Chemistry 288
30365–30372. (doi:10.1074/jbc.M113.504845)
Smyth GK 2005 Limma: linear models for microarray data. In
Bioinformatics and Computational Biology Solutions using R and
Bioconductor, pp 397–420. Eds R Gentleman, V Carey, S Dudoit,
R Irizarry & W Huber. New York: Springer.
Suh JH, Sieglaff DH, Zhang A, Xia X, Cvoro A, Winnier GE & Webb P 2013
SIRT1 is a direct coactivator of thyroid hormone receptor b1 with
gene-specific actions. PLoS ONE 8 e70097. (doi:10.1371/journal.pone.
0070097)
Tabas-Madrid D, Nogales-Cadenas R & Pascual-Montano A 2012
GeneCodis3: a non-redundant and modular enrichment analysis
tool for functional genomics. Nucleic Acids Research 40 W478–W483.
(doi:10.1093/nar/gks402)
Thakran S, Sharma P, Attia RR, Hori RT, Deng X, Elam MB & Park EA 2013
Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid
hormone. Journal of Biological Chemistry 288 807–818. (doi:10.1074/jbc.
M112.437970)
Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R,
Mohammadi M, Gerard RD, Dechow PC et al. 2012 Fibroblast growth

Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 07/04/2022 03:50:28PM
via free access

Research

A ZHANG

and others

factor 21 promotes bone loss by potentiating the effects of peroxisome
proliferator-activated receptor g. PNAS 109 3143–3148. (doi:10.1073/
pnas.1200797109)
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R,
Li YS, Lindberg RA et al. 2009 Fibroblast growth factor 21 reverses
hepatic steatosis, increases energy expenditure, and improves insulin
sensitivity in diet-induced obese mice. Diabetes 58 250–259.
(doi:10.2337/db08-0392)

Thyroid hormone/FGF21
interactions

224:3

301

Yuan C, Lin JZ, Sieglaff DH, Ayers SD, Denoto-Reynolds F, Baxter JD &
Webb P 2012 Identical gene regulation patterns of T3 and selective
thyroid hormone receptor modulator GC-1. Endocrinology 153
501–511. (doi:10.1210/en.2011-1325)
Zhang CY, Kim S, Harney JW & Larsen PR 1998 Further characterization
of thyroid hormone response elements in the human type 1
iodothyronine deiodinase gene. Endocrinology 139 1156–1163.
(doi:10.1210/endo.139.3.5849)

Journal of Endocrinology

Received in final form 8 December 2014
Accepted 11 December 2014
Accepted Preprint published online 11 December 2014

http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0440

Ñ 2015 Society for Endocrinology
Printed in Great Britain

Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 07/04/2022 03:50:28PM
via free access

